A, low risk of bias:the study met almost criteria; B, moderate risk of
bias :the study met part or unclear for one or more quality criteria;
C, high risk of bias :the study was not met or included
criteria;†ANOVA:analysis of
variance;‡ITT:Intention-to-treat;§NA:
not available;
Figure 1 . PRISMA flow diagram demonstrating the progress of
study evaluation throughout the review.
Figure 2 . Forest plots of
(A):the relationship between patient with asthma or allergic rhinitis
use montelukast and the occurrence of neuropsychiatric events and (B):
funnel plot of the included studies.
Figure 3 . Forest plots of patients with asthma or rhinitis have
been linked to a neuropsychiatric event called headache
Figure 4 . Forest plots of (A):the relationship between the use
of montelukast and neuropsychiatric events in asthma patients
and(B)the relationship between the use of montelukast and
neuropsychiatric events in patients with rhinitis.
Figure 5 . Forest plots of (A):the relationship between
montelukast and neuropsychiatric events in adult patients with asthma or
rhinitis and (B): the relationship between montelukast and
neuropsychiatric events in children patients with asthma or rhinitis.
Figure 6 . Funnel plot of(A):the included studies based on the
patient with montelukast or common clinical drugs analysis and forest
plots of (B):the neuropsychiatric events between montelukast and
budesonide versus budesonide alone in asthmatic patients and (C): the
occurrence of neuropsychiatric events in patients with allergic rhinitis
compared with montelukast combined with loratadine versus loratadine
alone